特里戈内林通过肠道微生物组变化改善HFpEF小鼠的新陈代谢和心脏功能-介导AMPK激活
Zhe Cheng1,2, Xiaowen Wang3, Jiang Yu1
1Department of Cardiovascular Medicine, Cardiovascular Research CenterCenter, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|November 6, 2025
概括
特里戈内林补充剂通过恢复肠道细菌和激活AMPK来改善心力衰竭中的心脏功能. 这种天然化合物显示出对HFpEF的治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 代谢学 代谢学 代谢学
- 微生物组研究 微生物组研究
背景情况:
- 保持喷射分数的心力衰竭 (HFpEF) 是一种常见的心血管疾病,治疗选择有限.
- 代谢功能障碍和肠道功能障碍与HFpEF病变产生有关.
- 确定新的治疗点对于管理HFpEF至关重要.
研究的目的:
- 调查代谢物在HFpEF中的作用.
- 在HFpEF的小鼠模型中评估trigonelline的治疗潜力.
- 阐明底层的机制,Trigonelline对心脏功能和新陈代谢的影响.
主要方法:
- 使用高脂肪饮食和L-NAME的小鼠诱导HFpEF.
- 不针对性的代谢学分析,以识别关键代谢物.
- 口服三素和评估心脏功能,代谢参数和肠道微生物群组成.
- 用AMP激活蛋白激酶 (AMPK) 路径分析.
主要成果:
- 在HFpEF小鼠心脏中,trigonelline显著降低.
- 在HFpEF小鼠中,补充trigonelline可以改善心脏功能,肥胖,胰岛素抵抗和肝损伤.
- 特里戈内林的保护作用是由肠道微生物群依赖的AMPK激活和肠道微生物组平衡的恢复 (减少Firmicutes,增加Bacteroidetes) 介导的.
结论:
- 特里戈内林补充剂显示出对HFpEF具有显著的治疗潜力.
- 该机制涉及恢复肠道微生物组失调和激活AMPK信号传递.
- 特里戈内林为HFpEF患者提供了一个有前途的新疗法策略.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:25cAMP-dependent Protein Kinase Pathways
8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207